Overall Survival Is Not a Realistic End Point for Clinical Trials of New Drugs in Advanced Solid Tumors: A Critical Assessment Based on Recently Reported Phase III Trials in Colorectal and Breast Cancer
- 15 May 2003
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (10) , 2045-2047
- https://doi.org/10.1200/jco.2003.99.089
Abstract
LetterSCOPUS: le.jinfo:eu-repo/semantics/publisheKeywords
This publication has 7 references indexed in Scilit:
- Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialJournal of Clinical Oncology, 2002
- Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2001
- Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter TrialJournal of Clinical Oncology, 2001
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2000
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialPublished by Elsevier ,2000
- Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal CancerJournal of Clinical Oncology, 2000